St Olavs Hospital
Trondheim, Norway
NCT Number: NCT03101124
Tranexamic acid is a drug that prevents clotted blood from dissolving and hence reduces bleeding. It is routinely given intravenously in many surgical situations where there is a risk of major bleeding. Concerns regarding possible adverse effects from intravenous use prevents a more widespread use, even in smaller surgeries. Topical application - using the drug directly on the wound surface- may give a higher concentration at the site of bleeding but a lower concentration in the rest of the body, and hence a lower risk of adverse effects. Here it will be investigated to what extent a defined dose of the drug is absorbed systemically - into the blood stream - when it is applied topically. This will then be compared to the concentration in the blood stream when administered intravenously. Blood samples will be obtained at defined time intervals after administration from patients receiving topical and patients receiving intravenous administration of the same single dose of tranexamic acid. Will less of the drug enter the blood stream if it is applied directly to the wound?
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2
Trondheim, Norway
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Wound surface moistened with 20 ml of tranexamic acid 25 mg/ml (total dose 500 mg) prior to wound closure
Other names: Cyclokapron
200 ml of tranexamic acid 5 mg/ml (total dose 1 g) as a bolus instilled into the wound cavity after wound closure, which will remain in the cavity until the activation of drains one hour later
Other names: Cyclokapron
1 g of tranexamic acid administered intravenously in accordance with prevailing routines directly prior to planned surgical procedure.
Other names: Cyclokapron
Time frame: 24 hours
as described by the Area Under the (time-concentration) Curve (AUC) from 0 to infinity, alternatively from 0 to 240 minutes if drug levels after 24 hours do not allow for such extrapolation
Time frame: 24 hours
if AUC from 0 to infinity turns out to be the primary end point.
Time frame: 24 hours
Maximal level of serum tranexamic acid in measurements
Time frame: 24 hours
Timepoint for serum tranexamic acid read from AUC
Time frame: 24 hours
Reading elimination half-life from AUC
Time frame: four weeks
Possible adverse reactions or other complaints observed or reported by the patient - telephone interview
Time frame: 1 day
Possible adverse reactions or complaints observed or reported on the first postoperative day - clinical observation
St. Olavs Hospital
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05177887
Bleeding, Hemorrhage
Hradec Králové, Czechia
View Trial DetailsNCT05177874
Bleeding, Hemorrhage
Hradec Králové, Czechia
View Trial DetailsNCT06634030
Surgical Wound, Wound Healing
Nashville, Tennessee, United States
View Trial DetailsNCT07601919
Surgical Wound, Wounds and Injuries
Rawalpindi, Punjab Province, Pakistan
View Trial Details